Clinical Trial Update: Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma [Phase 1]

View source ↗

Summary

A Phase I trial of TH1 dendritic cell immunotherapy for angiosarcoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma

Drugs mentioned

• TH1 Dendritic Cell Immunotherapy

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Angiosarcoma | Phase 1 | Status: WITHDRAWN